
The Senate Finance Committee today held the second in a planned series of bipartisan hearings on high prescription drug prices, which featured executives from drug companies AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer and Sanofi.